The global pharmaceutical sector faces challenges with rising trade tensions leading to new tariffs on drug exports, straining supply chains and increasing operating costs. Merck & Co. (MRK) is navigating this landscape with a focus on cost-cutting and innovation, as its patent protection for Keytruda expires in 2028.

Merck boasts a market capitalization of $196.1 billion, anchored by a strong oncology portfolio and expanding animal health business. Despite a 20.3% decline in shares year-to-date, Merck offers a robust 4.15% dividend yield and attractive valuation metrics, making it an appealing choice for income investors.

The latest earnings report highlighted Merck’s resilience in oncology and animal health, with total worldwide sales at $15.8 billion and Keytruda contributing significantly to quarterly sales. The company faces challenges such as tariff-driven headwinds and patent cliffs, prompting a $3 billion cost-cutting plan to drive efficiency and savings by 2027.

Merck’s strategic initiatives include a $10 billion acquisition of Verona Pharma for pipeline diversification and therapeutic innovation. The company is investing in digital transformation with partnerships like Veeva Systems to enhance commercial capabilities and drive future product launches. Analyst sentiment is cautiously upbeat, with a mean price target of $103.18, suggesting a 30.1% upside potential from recent levels.

While some analysts remain neutral on Merck due to challenges ahead, investors should monitor the company’s progress with cost-cutting measures, acquisitions like Verona Pharma, and managing the Keytruda patent expiration. Success in pipeline launches and strategic deals will be key to driving stock performance. Until clear momentum is demonstrated, expect volatility in Merck’s shares.

Read more at Yahoo Finance: This Blue-Chip Dividend Stock Is Stuck in the Tariff Crosshairs. Can Cost Cuts Save the Day?